Research and Markets (http://www.researchandmarkets.com/research/s9d5hv/global)
has announced the addition of the "Global
Endometriosis Market 2014-2018" report to their offering.
This report covers the present scenario and the growth prospects of the
Global Endometriosis market for the period 2013-2018. To calculate the
market size, the report considers the revenue generated from the sales
of various drugs used in the treatment of endometriosis that are
available in the market.
The launch of high-cost GnRH antagonist therapies such as AbbVie's
Elagolix (which is in phase III trial) is expected during the forecast
period. Currently, the market is being served by low-cost alternatives
such as combined OCPs, NSAIDs, and progestins. Patients tend to choose
low-cost alternatives, which will be a challenge to the high-cost GnRH
According to the report, the Global Endometriosis market is driven by a
large amount of unmet need due to lack of diagnostics and lack f
approved treatment options for the disease. Currently, the diagnosis is
mainly through non-invasive methods where standard diagnostic procedures
are not available. Thus, development of proper diagnostic tools for the
early detection of the disease will increase the number of patients
treated. A lack of approved drugs for the treatment of endometriosis
creates a lucrative space for companies to develop new therapy options
to enter the market.
Further, the report states that one of the main challenges is patent
expiries of endometriosis drugs which leads to loss of exclusive rights
of branded products followed by the introduction of low-priced generics
into the market. This poses a potential threat to the established
companies that spend a huge amount on R&D.
The report contains a comprehensive market and vendor landscape in
addition to a SWOT analysis of the key vendors.
Other Prominent Vendors
Key Topics Covered:
For more information visit http://www.researchandmarkets.com/research/s9d5hv/global
[ Back To NFVZone's Homepage ]